论文部分内容阅读
目的研究医疗机构药品集中招标采购的现状及存在的问题,为药品招标工作提供参考,以求进一步规范我国药品招标工作。方法随机抽取2006年、2007年、2008年河南某市药品中标目录中通用名、规格、剂型、产地均相同的药品,对其降价率、降价幅度和平均每一通用名药品中标数量进行统计学分析。结果 2008年中标药品总数达到8492个较2006年、2007年中标药品总数分别增长了3.75倍和1.52倍。三年度平均每一品种中标药品数量有统计学意义;中标药品降价率和降价幅度之间亦有统计学意义。结论三年来,通过药品集中招标采购,药品中标价不断下降,减轻了患者的医药费用负担,但药品降价率、降价幅度逐年减少;中标药品总数的飞速增长,极易引发严重的促销和二次促销。
Objective To study the status quo and existing problems of centralized bidding and purchasing of pharmaceuticals in medical institutions and to provide references for bidding for medicines in order to further standardize the bidding of medicines in our country. Methods The drugs with the same name, specifications, dosage form and origin in the bidding list of drugs in a city of Henan in 2006, 2007 and 2008 were randomly selected and statistically analyzed for the price-cutting rate, the price-cutting rate and the average number of successful bidders for each generic drug analysis. Results The total number of successful drugs in 2008 reached 8492 compared with 2006 and 2007, respectively, the total number of successful drugs increased by 3.75 times and 1.52 times. In the three years, the average number of successful bidders for each variety was statistically significant. There was also a statistically significant difference between the price-cutting rate of bid-winning drugs and the price reduction. Conclusions In the past three years, bidding and purchasing through drug centralized bidding continued to drop, reducing the patient’s medical cost burden, but the drug price-cutting rate and the rate of price decrease year by year. The rapid growth of the total number of successful bidders could easily lead to serious promotions and secondary Promotions.